GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Argos Therapeutics Inc (FRA:77AA) » Definitions » Debt-to-Revenue

Argos Therapeutics (FRA:77AA) Debt-to-Revenue : 3.71 (As of Sep. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Argos Therapeutics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Argos Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2018 was €5.59 Mil. Argos Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2018 was €10.25 Mil. Argos Therapeutics's annualized Revenue for the quarter that ended in Sep. 2018 was €4.28 Mil. Argos Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Sep. 2018 was 3.70.


Argos Therapeutics Debt-to-Revenue Historical Data

The historical data trend for Argos Therapeutics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argos Therapeutics Debt-to-Revenue Chart

Argos Therapeutics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only 1.60 11.76 62.31 42.18 10.24

Argos Therapeutics Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 92.82 2.91 0.81 88.13 3.71

Competitive Comparison of Argos Therapeutics's Debt-to-Revenue

For the Biotechnology subindustry, Argos Therapeutics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Argos Therapeutics's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Argos Therapeutics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Argos Therapeutics's Debt-to-Revenue falls into.



Argos Therapeutics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Argos Therapeutics's Debt-to-Revenue for the fiscal year that ended in Dec. 2017 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(6.188 + 10.253) / 1.605
=10.24

Argos Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Sep. 2018 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(5.59 + 10.252) / 4.276
=3.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2018) Revenue data.


Argos Therapeutics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Argos Therapeutics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Argos Therapeutics (FRA:77AA) Business Description

Traded in Other Exchanges
N/A
Address
4233 Technology Drive, Durham, NC, USA, 27704
Argos Therapeutics Inc is a biopharmaceutical company. It is engaged in the development and commercialization of immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis.

Argos Therapeutics (FRA:77AA) Headlines

No Headlines